NX Development Corp

NXDC is developing Gliolan™ as an Orphan drug which enhances brain tumor visualization improving tumor removal and outcomes. https://vimeo.com/122150642

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Louisville, KY, US
  • Currency USD
  • Founded November 2010
  • Employees 6
  • Website nxdevcorp.com

Company Summary

NXDC has exclusive US rights for Gliolan™ (5-aminolevulinic acid), which is approved ex-US with 58,000 patients treated. Gliolan™ is in high demand and is expected to be available in 2016 through an FDA program at leading US brain tumor centers. Gliolan™ improves tumor resection aligning strategic interests with blockbuster glioblastoma therapies. Funds on hand enable FDA approval (in 2016); a new $3M accelerates Gliolan’s market penetration

Team

  • Alan Ezrin

  • Jeffery Cooper
    Chief Commercial Officer

    Jeff Cooper Chief Commercial Officer

    35+ years’ experience as a financial executive.
    CPA, Certified Forensic Consultant and Fellow American College of Forensic Examiners.
    Former manager at Deloitte and former Managing Partner of Cooper and Cobb, CPAs.
    Former CFO of the publicly traded company Spinnaker Software.
    Consulted to numerous Companies at their start including iRobot, Northern Light Technologies and Palm Technologies.
    .

  • Joe Wyse
    Chief Operational Officer

    25+ years’ experience employed directly or as a consultant to life science companies. He has broad strategic consulting, business development and operational experience leading several startup pharmaceutical, biotech, CRO, and device companies. Founding CEO of Coldstream Labs, Lexington KY
    Dr. Wyse served as a Director at PriceWaterhouseCoopers and Aronex and LifeCell. Dr. Wyse holds a Ph.D. in chemistry from the University of Kentucky.

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free